Spiralyde A, an Antikinetoplastid Dolabellane from the Brown Alga Dictyota spiralis.

Olfa Chiboub,José Javier Fernández,Jacob Lorenzo-Morales,Ines Sifaoui,Ana R. Díaz-Marrero,José E. Piñero,Mondher Mejri,Manef Abderrabba

doi:10.3390/md17030192

Olfa Chiboub, José Javier Fernández + Show 6 more

Open Access

https://doi.org/10.3390/md17030192

Copy DOI

Journal: Marine Drugs	Publication Date: Mar 25, 2019
Citations: 20	License type: CC BY 4.0

Affiliation: University of La Laguna, University of Carthage

Abstract

Bioassay-guided fractionation of the antikinetoplastid extract of the brown alga Dictyota spiralis has led to the isolation of spiralyde A (1), a new dolabellane aldehyde, along with other five known related diterpenes (2–6). Their structures were determined by HRESIMS, 1D and 2D NMR spectroscopy, and comparison with data reported in the literature. The antiparasitic activity of all compounds was evaluated. Spiralyde A (1) and the known compound 3,4-epoxy-7,18-dolabelladiene (2) were the most active compounds against Leishmania amazonensis and Trypanosoma cruzi. Spiralyde A (1) was the most potent compound, comparable to benznidazole, the reference drug for trypanocidal activity.

Highlights

Infections caused by kinetoplastid parasites, Trypanosoma brucei, Trypanosoma cruzi (Chagas disease), and Leishmania spp. are considered neglected tropical diseases (NTD) by the World Health Organization
Despite numerous marine molecules that have been tested to date in vitro for their trypanocidal and leishmanicidal activity, mainly obtained from sponges and corals [3,4,5], none has reached the market for the treatment of NTDs caused by kinetopastid parasites
Dictyota spiralis was collected off the intertidal zone of the Northwest coast of Tunisia

Summary

Introduction

Infections caused by kinetoplastid parasites, Trypanosoma brucei (human African trypanosomiasis, sleeping sickness), Trypanosoma cruzi (Chagas disease), and Leishmania spp. (leishmaniasis) are considered neglected tropical diseases (NTD) by the World Health Organization. Infections caused by kinetoplastid parasites, Trypanosoma brucei (human African trypanosomiasis, sleeping sickness), Trypanosoma cruzi (Chagas disease), and Leishmania spp. (leishmaniasis) are considered neglected tropical diseases (NTD) by the World Health Organization. Occurrence of drug resistance, toxicity and the lack of effective chemotherapy for the treatment of leishmaniasis and trypanosomiasis, urge a wide investigation to access new chemical entities with therapeutic potential [1]. Marine natural products have provided the pharmaceutical industry with many potent compounds [2]. Despite numerous marine molecules that have been tested to date in vitro for their trypanocidal and leishmanicidal activity, mainly obtained from sponges and corals [3,4,5], none has reached the market for the treatment of NTDs caused by kinetopastid parasites.

Methods

Results

Conclusion